Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

NCT00524667 is registered in ClinicalTrials.gov with CancerCare Manitoba as lead sponsor.

NCT NCT00524667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00524667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia
Lead sponsor
CancerCare Manitoba
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2008
Completion date
July 31, 2011
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia